Jun 2026 (Q2 FY26) — Aug 6, 2026
GoodRx Q2 FY26 — Strong Pharma Direct and Subscription Growth Drive Raised Outlook
Read the full callGoodRx (GDRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
GoodRx earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 200 | −1.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 11.8 | −1.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 8.5 | −33.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$3.37 +0.30% · +$0.01
Performance −12.0% 1Y
1Y: $3.83 on 17 Oct 2025 → $3.37. High $3.98 (20 Oct 2025), low $1.87 (27 Feb 2026).
- Previous close
- $3.36
- 52-week range
- $1.87 – $3.98
- One year
- −15.33%
Overview
- Symbol
- GDRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
GoodRx earnings calls (GDRX)
Financials
What the filings say
Net profit, year on year: −34% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 199 | 203 | 203 | 196 | 195 | 194 | 200 |
| Expenses | 175 | 180 | 180 | 176 | 181 | 172 | 180 | 177 |
| Operating profit | 20 | 18 | 23 | 27 | 15 | 23 | 14 | 24 |
| Operating margin | 10.4% | 9.2% | 11.5% | 13.2% | 7.5% | 11.7% | 7.2% | 11.8% |
| Other income | -12 | -7 | -7 | -7 | -9 | -8 | -8 | -8 |
| Interest | 12 | 11 | 11 | 11 | 11 | 10 | 10 | 10 |
| Profit before tax | 8 | 11 | 17 | 20 | 6 | 14 | 6 | 15 |
| Tax rate | 51.1% | 40.9% | 33.7% | 34.4% | 81.7% | 61.8% | 79.3% | 44.8% |
| Net profit | 4 | 7 | 11 | 13 | 1 | 5 | 1 | 9 |
| EPS ($ per share) | 0.01 | — | 0.03 | 0.04 | 0 | — | 0 | 0.03 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -1,097 | -1,390 | -1,416 | -1,449 | -1,457 | -1,441 | -1,411 |
| Total liabilities | — | 737 | 759 | 776 | 790 | 827 | 663 | 788 |
| Fixed assets | — | 2 | 23 | 22 | 20 | 16 | 13 | 12 |
| Total assets | — | 387 | 1,470 | 1,608 | 1,605 | 1,589 | 1,388 | 1,404 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 45 | 83 | 131 | 179 | 147 | 138 | 184 | 168 |
| Cash from investing | -3 | -37 | -92 | -179 | -210 | -56 | -70 | -120 |
| Cash from financing | -25 | -55 | 906 | -31 | -120 | -167 | -337 | -234 |
| Net cash flow | 17 | -9 | 946 | -30 | -184 | -85 | -224 | -187 |
| Capital expenditure | -1 | -1 | -21 | -5 | -4 | -1 | -1 | -4 |
| Free cash flow | 44 | 82 | 111 | 174 | 143 | 137 | 183 | 164 |
Insider filings
122 filings between Oct 26, 2025 and Oct 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$9.68M
14 sales by 1 insider
Compensation
not trading decisions- 14
- Award — granted as compensation
- 46
- Option exercise — converted options into shares
- 42
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 conversions, 2 gifts, 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| FRANCISCO PARTNERS IV, L.P. | — | $9.68M | Aug 26, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Barnes Wendy Lynn See Remarks | Tax withheld | 50,021 | $169.1K |
| Oct 15, 2026 | Barnes Wendy Lynn See Remarks | Tax withheld | 22,232 | $75.1K |
| Oct 15, 2026 | Barnes Wendy Lynn See Remarks | Option exercise | 110,963 | — |
| Oct 15, 2026 | Fengler Justin See Remarks | Tax withheld | 14,247 | $48.2K |
| Oct 15, 2026 | Barnes Wendy Lynn See Remarks | Tax withheld | 48,203 | $162.9K |
| Oct 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Tax withheld | 2,948 | $10.0K |
| Oct 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Option exercise | 5,793 | — |
| Oct 15, 2026 | Barnes Wendy Lynn See Remarks | Option exercise | 51,177 | — |
| Oct 15, 2026 | Barnes Wendy Lynn See Remarks | Option exercise | 115,149 | — |
| Oct 15, 2026 | Fengler Justin See Remarks | Option exercise | 32,490 | — |
| Sep 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Tax withheld | 1,069 | $3.8K |
| Sep 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Option exercise | 2,101 | — |
| Sep 15, 2026 | Fengler Justin See Remarks | Option exercise | 752 | — |
| Sep 15, 2026 | Fengler Justin See Remarks | Tax withheld | 1,024 | $3.6K |
| Sep 15, 2026 | Fengler Justin See Remarks | Option exercise | 2,335 | — |
| Sep 15, 2026 | Fengler Justin See Remarks | Tax withheld | 330 | $1.2K |
| Aug 26, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 439,310 | $1.54M |
| Aug 26, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 210,378 | $739.0K |
| Aug 26, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 213,401 | $749.6K |
| Aug 26, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 433,088 | $1.52M |
| Aug 25, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 64,090 | $220.8K |
| Aug 25, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 63,183 | $217.7K |
| Aug 24, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 72,309 | $250.3K |
| Aug 24, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 71,285 | $246.8K |
| Aug 21, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 136,379 | $476.9K |
| Aug 21, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 138,338 | $483.7K |
| Aug 20, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 233,415 | $821.7K |
| Aug 20, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 213,844 | $752.8K |
| Aug 19, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 234,304 | $827.1K |
| Aug 19, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Sale | 237,671 | $839.0K |
| Aug 19, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Other | 1,142,357 | $0 |
| Aug 19, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Other | 3,596,648 | $0 |
| Aug 19, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Conversion | 4,995,903 | — |
| Aug 19, 2026 | FRANCISCO PARTNERS IV, L.P. 10% owner | Conversion | 2,504,097 | — |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Option exercise | 2,636 | — |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Tax withheld | 858 | $3.2K |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Option exercise | 1,686 | — |
| Aug 15, 2026 | Fengler Justin See Remarks | Tax withheld | 11,212 | $41.8K |
| Aug 15, 2026 | Fengler Justin See Remarks | Option exercise | 25,568 | — |
| Aug 15, 2026 | Fengler Justin See Remarks | Tax withheld | 2,803 | $10.5K |
| Aug 15, 2026 | Fengler Justin See Remarks | Tax withheld | 2,817 | $10.5K |
| Aug 15, 2026 | Fengler Justin See Remarks | Option exercise | 6,392 | — |
| Aug 15, 2026 | Fengler Justin See Remarks | Option exercise | 6,423 | — |
| Aug 15, 2026 | Fengler Justin See Remarks | Tax withheld | 4,575 | $17.1K |
| Aug 15, 2026 | Fengler Justin See Remarks | Option exercise | 10,149 | — |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Tax withheld | 638 | $2.4K |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Option exercise | 1,252 | — |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Tax withheld | 2,311 | $8.6K |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Option exercise | 4,541 | — |
| Aug 15, 2026 | Chan Thomas (TC) Chief Accounting Officer | Tax withheld | 1,342 | $5.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for GoodRx Holdings, Inc.
Free account. Everything above stays public.
Write why you follow GoodRx Holdings, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading